ClinicalTrials.gg
CompletedNCT05244668Updated Mar 27, 2026

Multicenter Validation of the Salivary miRNA Signature of Endometriosis

An observational study in Endometriosis, sponsored by ZIWIG. Completed at 18 sites in 2 countries. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by ZIWIG · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,140
Ages
18 Years to 43 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.

Enrollment
7th of 58
1,140 · median 133
Started
2021
with 11 others
Observational
58 of 128
23 open now
Registered
64th of 128
by date
Lead sponsor
6 of 128
ZIWIG

Among the 128 studies in Endometriosis with a site in France, this one is the 7th largest by enrollment of the 58 observational ones that give a count, is one of 12 that started in 2021, is one of 58 observational ones, and was the 64th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 43 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Endometriosis with a site in France, or all of them as a file.
02

Study summary

ENDOmiARN Salive Test is a multicentre external validation study of a salivary signature of endometriosis carried out in France in Obstetrics and Reproductive Medicine departments, in order to evaluate its performance and discuss its use in clinical practice. The clinical application is to significantly reduce the time to diagnosis and improve the care pathway for endometriosis.

The study population is made up of women aged 18 to 43 years with formally diagnosed endometriosis or suspected endometriosis who are already receiving either medical (MAP) or surgical treatment as part of their routine care.

The patients concerned by the study are managed without any change in the care pathway, nor any change in the therapeutic indications, nor any change in the diagnostic examinations (imaging or biology) required according to the context, which are carried out in accordance with the HAS recommendations.

In this study, the management and follow-up of patients :

  • Are not imposed by the study: the doctor remains free to make medical prescriptions (treatments and examinations) and to determine the interval between consultation visits,
  • Are not modified in comparison with the usual follow-up, except for the performance of :

    • Collection of saliva
    • Electronic collection of the answers to the questionnaires completed by the patient
03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • miRNA
  • MAP
  • machine learning algorithms
04

Who can participate

Ages eligible
18 Years to 43 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

The study population is made up of women aged 18 to 43 years with a formal diagnosis of endometriosis or suspected endometriosis.

The patients concerned by the study are already receiving either medical (MAP) or surgical care in a department of Obstetrics and Reproductive Medicine.

All these patients already benefit from validation of therapeutic indications in a multidisciplinary consultation meeting (medical-surgical or fertility RCP).

The patients concerned by the study are managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic examinations (imaging or biology) necessary according to the context, which are carried out according to the recommendations of the HAS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged between 18 and 43 years,
  • Patient having dated and signed the consent form,
  • Patient affiliated to the French health system,
  • Patient with pelvic MRI and/or pelvic ultrasound,
  • Patient from one of the 3 study populations:

    • Patient with a formal endometriosis diagnosed by clinical examination and imaging AND an indication for specialised endometriosis follow-up or medically assisted procreation (MAP) or surgery validated by RCP (in routine care);
    • Patient with suspected endometriosis for whom the diagnosis is the source of a discrepancy between clinical and radiological data AND a surgical indication validated by RCP (in routine care);
    • Patient with a gynaecological indication for surgery of the small pelvis by laparoscopy or laparoscopy validated in RCP (in routine care) AND symptoms suggestive of endometriosis (dysmenorrhoea, ....)(1).

Exclusion criteria

Exclusion Criteria:

  • Patient with recurrence of deep endometriosis (excluding endometrioma),
  • Patient with endometriosis of the torus and/or utero-sacral ligaments without indication for surgery,
  • Patient with parietal endometriosis alone without indication for surgery,
  • Patient with adenomyosis alone on imaging without indication for surgery,
  • Patient with gynaecological infection requiring surgical management,
  • Pregnant patient,
  • Patient infected with the (HIV),
  • Patient with significant difficulties in reading or writing the French language,
  • Patient with a personal history of cancer,
  • Patient unable to comply with study and/or follow-up procedures,
  • Patient who has objected to the collection of her data.
  • Patient participating in another clinical research study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,140 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. At least a 90% Sensitivity (True Positive Rate) of Endometriosis diagnotic confirmation using a miRNA signature

    External validation of the salivary signature of endometriosis miRNAs

    Time frame: Through the end of study inclusions, an average of 1 year

  2. At least a 90% Specificity (True Negative Rate) of Endometriosis diagnotic confirmation using a miRNA signature

    External validation of the salivary signature of endometriosis miRNAs

    Time frame: Through the end of study inclusions, an average of 1 year

07

Study locations

18 sites
  • CHU Québec
    Québec, Canada
  • CHU Strasbourg - Hôpital Hautepierre
    Strasbourg, Alsace 67200, France
  • CHU de Caen
    Caen, Calvados 14000, France
  • Clinique Tivoli
    Bordeaux, Gironde 33000, France
  • CHU Toulouse - Hôpital Rangueil
    Toulouse, Haute Garonne 31059, France
  • Clinique Pasteur
    Toulouse, Haute-Garonne 31300, France
  • Clinique La Sagesse
    Rennes, Ille Et Vilaine 35000, France
  • Cabinet de Gynécologie Médicale
    Lyon, Rhône 69002, France
  • CHU Rouen
    Bois-Guillaume, Seine-Maritime 76230, France
  • Hôpital BICETRE
    Le Kremlin-Bicêtre, Val De Marne 94275, France
  • Centre médical des Pyramides
    Maurepas, Yvelines 78310, France
  • CHU Angers
    Angers, 49933, France
  • CH Bastia
    Bastia, 20600, France
  • HCL
    Lyon, 69000, France
  • Groupe Hospitalier Saint Josef
    Paris, 75014, France
  • Centre d'imagerie Manin Crimée
    Paris, 75019, France
  • CHU Tenons
    Paris, 75020, France
  • CHU Rennes
    Rennes, 35000, France
08

References and documents

Publications

  • Bendifallah S, Roman H, Suisse S, Spiers A, Petit E, Delbos L, Dabi Y, Touboul C, Dennis T, Merlot B, Sauvanet E, Fauvet R, Jamard E, Clotilde H, Morgane P, Fedida B, Nyangoh K, Lavoue V, Roger CM, Lucas N, Darnaud T, Boudy AS, Genre L, Leguevaque P, Akldios C, Benjoar M, Chantalat E, Tanguy Le Gac Y, Poilblanc M, Rousset P, Fernandez H, Golfier F, Descamps P. Validation of a Saliva Micro-RNA Signature for Endometriosis. NEJM Evid. 2025 Nov;4(11):EVIDoa2400195. doi: 10.1056/EVIDoa2400195. Epub 2025 Oct 28. PubMed 41147827 ↗
  • Bendifallah S, Dabi Y, Suisse S, Delbos L, Spiers A, Poilblanc M, Golfier F, Jornea L, Bouteiller D, Fernandez H, Madar A, Petit E, Perotte F, Fauvet R, Benjoar M, Akladios C, Lavoue V, Darnaud T, Merlot B, Roman H, Touboul C, Descamps P. Validation of a Salivary miRNA Signature of Endometriosis - Interim Data. NEJM Evid. 2023 Jul;2(7):EVIDoa2200282. doi: 10.1056/EVIDoa2200282. Epub 2023 Jun 9. PubMed 38320163 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jan 2023, 12 months.

Of 185 observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Feb 17, 2022
StartActual
Dec 15, 2021
Primary completionActual
Jan 6, 2023
CompletionActual
Feb 28, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05244668
Lead sponsor
ZIWIG
Collaborators
Monitoring Force Group, iGenSeq
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Dec 15, 2021
Primary completion
Jan 6, 2023
Completion
Feb 28, 2026
Last update
Mar 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion